Drugmaker Adamas Pharmaceuticals Inc said its lead experimental drug met the main goal of a late-stage study.
The company said its drug, amantadine HCl, significantly reduced dysfunctional movement, a side effect of levodopa, a drug used to treat Parkinson's patients.
Patients treated with the drug showed 23 percent reduction in dysfunctional movement at twelve weeks compared to placebo, company said.
Emeryville, California-based Adamas said it is also conducting another late-stage study to evaluate effectiveness of 340 mg dose of amantadine HCl given once daily at bedtime.
The drug had received orphan drug status from U.S. Food and Drug Administration in April which gives it several incentives including seven-year marketing exclusivity.
(Reporting by Vidya L Nathan and Anjali Rao Koppala in Bengaluru; Editing by Shounak Dasgupta)
0 nhận xét:
Đăng nhận xét